Clinical Trial Update: Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating daily 5 mg versus 10 mg everolimus in patients with neuroendocrine tumors; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Neuroendocrine Tumor Carcinoid
• Neuroendocrine Tumor of Pancreas
• Neuroendocrine Tumor of the Lung

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: AC Camargo Cancer Center | Conditions: Neuroendocrine Tumors, Progression | Phase 2 | Status: RECRUITING